Advanced Oncotherapy reaches deal with Birmingham NHS trust
By Josh White
Date: Thursday 20 Feb 2020
(Sharecast News) - Proton therapy developer Advanced Oncotherapy has reached agreement with University Hospitals Birmingham NHS Foundation Trust (UHB), the acute service provider delivering general hospital services for Birmingham and specialist treatments for the West Midlands and nationally, to install a 'LIGHT' system, it announced on Thursday.
The AIM-traded firm said that as part of the collaboration, Advanced Oncotherapy and UHB would also work together on various research and development activities associated with the use of LIGHT, to increase awareness of proton therapy for the treatment of cancer.
It said the collaboration between itself and UHB included an agreement that an appropriate revenue sharing arrangement would be implemented.
The deal envisaged that the LIGHT system would be installed on the UHB campus, with the installation and the treatment of the first patients subject to customary conditions and agreements being in place, including obtaining all relevant approvals, consents and authorisations, such as the certification of LIGHT.
Advanced Oncotherapy described UHB as one of the largest teaching hospital trusts in England, and one of the largest regional centres for non-surgical cancer treatment serving a regional, national and international population.
The hospital group sees and treats more than 2.2 million patients each year across its sites, including Queen Elizabeth Hospital Birmingham, Birmingham Heartlands Hospital, Solihull Hospital and Community Services, Good Hope Hospital in Sutton Coldfield, and Birmingham Chest Clinic.
From a regional aspect, UHB had established links with surrounding cancer units, and operates a number of smaller satellite units, allowing people to be treated as close to home as possible.
"Our trust is one of the largest regional centres for non-surgical cancer treatments in the UK, with our highly-specialised consultants working within a professional and well-established team to provide the best possible care to patients, their families and carers," said UHB chief executive officer Dr David Rosser.
"This collaboration will further strengthen our position as a Trust that embraces and develops the next generation of technology to continually improve outcomes and deliver healthcare that is fit for future generations."
Nicolas Serandour, chief executive officer of Advanced Oncotherapy, added that the firm was "pleased" to announce the collaboration with UHB.
"The collaboration is aimed at delivering best treatment modalities for patients and further establishes our network of scientific partners, positioning Advanced Oncotherapy at the forefront of clinical innovation.
"UHB's choice of Advanced Oncotherapy not only strengthens our leading position as technology disruptor in proton therapy, but also demonstrates our strong momentum and the clear opportunity we have to meet a significant unmet medical need."
Serandour noted that there were just 200 treatment rooms globally at present, but a need of at least 10,000 treatment rooms if 20% of patients undergoing radiotherapy were treated with proton therapy.
"With three partnerships announced in the last two months - the Cleveland Clinic, the London Clinic and the Mediterranean Hospital of Limassol - this fourth agreement is another important step for us as a company and it is in line with our continuous commitment to defeat cancer."
At 1542 GMT, shares in Advanced Oncotherapy were down 3.66% at 37.57p.
Email this article to a friend
or share it with one of these popular networks:
You are here: news
10 Lower Thames St,
London EC3R 6EN